USANA Health Sciences, Inc. (NYSE:USNA) is one of the 10 Best Debt Free Small Cap Stocks to Buy Now. USANA Health Sciences, Inc. (USNA) Launches an Upgraded Celavive Skincare Line, Features Refreshed Formulations and Five New Products On September 11, 2025, USANA Health Sciences, Inc. (NYSE:USNA) launched an upgraded Celavive skincare line, which features refreshed formulations and five new products. The upgrade includes a Vitalizing Serum with higher levels of active ingredients, a new Bi-Phase Makeup ...

Accessibility StatementSkip Navigation Breakthrough products and upgrades redefine cellular skincare for radiant, resilient skin SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- USANA (NYSE: USNA), a global leader in cellular nutrition, has unveiled the next evolution of its Celavive skincare brand. The launch includes potent new offerings, enhanced formulas, and the recruitment of two globally acclaimed beauty authorities as international spokespeople. This new era of Celavive combines advanced science with ...

Accessibility StatementSkip Navigation Innovative offerings designed to help people live more vibrant lives SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- USANA, a worldwide leader in the field of cellular nutrition, has announced a fresh set of advancements to its existing Nutritionals product line. This includes both enhanced versions of popular items and completely new offerings, all created to help individuals globally improve their health and wellness practices. To learn more about USANA's Nutritionals ...

Core Insights - The U.S. self-improvement industry is valued at $12 billion annually, highlighting its significance in personal and collective growth [1] - Kevin Guest, Executive Chairman of USANA Health Sciences, emphasizes that true success involves living a life of purpose and fulfillment, particularly during Self-Improvement Month [2] - Guest's personal journey illustrates the importance of self-improvement, emphasizing preparation and integrity as key lessons learned from past challenges [3][4] Company Overview - USANA Health Sciences is a global leader in health and wellness products, founded in 1992, and has a strong focus on social wellness as part of its business strategy [6] - The company operates in 25 countries, prioritizing clear communication to build trust with customers and distributors [7] Self-Improvement Initiatives - Guest encourages conducting a "Life Audit" with a trusted friend to gain external perspectives on personal growth areas [4] - Creating a "Reverse Bucket List" is suggested to reflect on past accomplishments, boosting confidence and identifying success patterns [4] - Learning practical "Survival Skills" is recommended as a form of self-improvement that enhances self-reliance and prepares individuals for unexpected situations [4][5]

Core Insights - USANA announced innovative new products, significant ingredient reformulations, and refreshed packaging at its 2025 Global Convention [1][3] - The introduction of the Health Professional Advisory Council aims to enhance product credibility and customer experience [5][6] Product Developments - New products include Circulate+, Core Aminos, Marine Collagen Peptides, and various Celavive skincare items [8] - Reformulated products consist of BiOmega, CellSentials, HealthPak, and several Celavive products [8] - Rebranded products include Celavive Creamy Foam Cleanser, Conditioning Makeup Remover, and Protective Day Cream/Lotion SPF 30 [8] Strategic Initiatives - The Health Professional Advisory Council will consist of industry experts to support product development and enhance customer experiences [5][6] - The company emphasizes its commitment to providing high-quality nutritional and lifestyle products, backed by over 30 years of trust [7]

Company Overview - USANA Health Sciences is a global leader in health and wellness products, founded in 1992, and operates in 25 countries [3] - The company emphasizes the importance of social wellness and clear communication to build trust with customers and distributors [3] Key Insights from Kevin Guest - Kevin Guest, Executive Chairman of USANA, promotes small daily habits for lasting wellness, emphasizing that wellness is a rhythm of life rather than a checklist [1][2] - Guest's book, "All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony," shares personal experiences and insights on overcoming anxiety and building confidence through preparation and small daily acts [2] Daily Habits for Wellness - Seven daily habits are outlined to support long-term well-being: 1. Start with Stillness: Five minutes of quiet can reset the day [4] 2. Fuel with Intention: Proper nutrition is essential for energy and mood [4] 3. Move Every Day: Movement can be simple and does not require a gym [4] 4. Speak Kindly, Especially to Yourself: Positive self-talk is crucial [4] 5. Choose Connection: Strong relationships are vital for wellness [4] 6. Protect Your Yes: Setting boundaries is a form of self-respect [4] 7. End With Gratitude: A daily gratitude practice can promote peace [4] Social Responsibility - Proceeds from Guest's book go towards feeding hungry children, with each purchase providing 40 meals [2]

Core Viewpoint - The article emphasizes the importance of value investing and highlights Rigel Pharmaceuticals (RIGL) and USANA Health Sciences (USNA) as strong value stock picks based on their financial metrics and Zacks Rank [2][3][8]. Company Analysis Rigel Pharmaceuticals (RIGL) - RIGL holds a Zacks Rank of 2 (Buy) and has a Value grade of A, indicating strong potential as a value stock [3]. - The company has a Price-to-Sales (P/S) ratio of 1.75, significantly lower than the industry average of 3.73, suggesting it may be undervalued [4]. - RIGL's Price-to-Cash Flow (P/CF) ratio is 9.33, compared to the industry average of 12.83, indicating a favorable cash outlook [5]. - Over the past year, RIGL's P/CF has fluctuated between a high of 96.38 and a low of -21.56, with a median of 10.07 [5]. USANA Health Sciences (USNA) - USNA also has a Zacks Rank of 2 (Buy) and a Value grade of A, making it another strong candidate for value investing [6]. - The stock is currently trading at a forward earnings multiple of 10.25 and a PEG ratio of 0.85, both significantly lower than the industry averages of 41.97 and 1.96, respectively [6]. - Over the last 12 months, USNA's P/E ratio has ranged from a high of 17.00 to a low of 7.83, with a median of 11.15, indicating potential undervaluation [7]. - USNA's Price-to-Book (P/B) ratio is 1.10, compared to the industry's 1.64, further supporting its value proposition [7].

Core Viewpoint - USANA Health Sciences (USNA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements. Institutional investors utilize these estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3][4]. - Rising earnings estimates for USANA Health suggest an improvement in the company's underlying business, which could lead to an increase in stock price as investors respond positively to this trend [4]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6]. - The Zacks rating system maintains a balanced distribution of "buy" and "sell" ratings across its universe of over 4,000 stocks, ensuring that only the top 20% receive a "Strong Buy" or "Buy" rating [8][9]. Earnings Estimate Revisions for USANA Health - For the fiscal year ending December 2025, USANA Health is expected to earn $2.62 per share, which remains unchanged from the previous year. However, the Zacks Consensus Estimate has increased by 0.4% over the past three months, indicating a positive trend in earnings expectations [7].

Core Insights - The article emphasizes the investment philosophy focused on small cap companies, highlighting the importance of identifying mispriced securities through understanding financial drivers and utilizing DCF model valuation [1] Group 1: Investment Philosophy - The investment approach is not confined to traditional categories such as value, dividend, or growth investing, but rather considers all prospects of a stock to assess risk-to-reward [1] Group 2: Market Focus - The investment strategy encompasses markets in the US, Canada, and Europe, indicating a broad geographical focus for potential investment opportunities [1]

Group 1: Merck KGaA (MKKGY) - MKKGY has a Zacks Rank of 1 (Strong Buy) and an A grade for Value, indicating it is a high-quality value stock [3] - The company has a PEG ratio of 1.85, which is lower than the industry average of 1.99, suggesting it may be undervalued [4] - MKKGY's P/CF ratio is 6.30, significantly lower than the industry average of 12.68, further indicating potential undervaluation [5] - Over the past year, MKKGY's PEG has fluctuated between 1.40 and 2.31, with a median of 2.01 [4] - The P/CF ratio has ranged from 5.95 to 17.18, with a median of 7.25 [5] Group 2: USANA Health Sciences (USNA) - USNA holds a Zacks Rank of 2 (Buy) and an A grade for Value, making it another strong candidate in the Medical - Drugs sector [6] - The company is currently trading at a forward earnings multiple of 10.36, which is significantly lower than the industry's average P/E of 42.68 [6] - USNA has a PEG ratio of 0.86, compared to the industry average of 1.99, indicating it may be undervalued [6] - Over the last 12 months, USNA's P/E has varied from 7.83 to 17.00, with a median of 11.26 [7] - The P/B ratio for USNA is 1.11, lower than the industry's price-to-book ratio of 1.63, suggesting further undervaluation [7] Group 3: Overall Valuation Insights - Both MKKGY and USNA exhibit strong Value grades, indicating they are likely undervalued based on key financial metrics [8] - The strength of earnings outlook for both companies enhances their attractiveness as value stocks at the moment [8]